Labelled interleukin-8 and medical uses thereof
AssigneesMallinckrodt Medical, Inc., Curators of the University of Michigan
InventorsLeon R. Lyle, Steven L. Kunkel
Life of this patent
Estimating the term…
Abstract
A method of imaging a target site in an animal's body in which a labelled CXC chemokine is introduced into the animal's body and allowed to accumulate at a target site which includes Interleukin-8 receptor molecules. The accumulated, labelled CXC chemokine is then detected so as to image the target site of the body.
Claims23
A method of imaging a target site in an animal body, comprising providing a radionuclide-labelled CXC chemokine, wherein C stands for cysteine and X stands for an amino acid, introducing a detectable amount of said labelled CXC chemokine into an animal's body, allowing the labelled CXC chemokine to accumlate at a target site of the animal's body, wherein neutrophils having Interleukin-8 receptor molecules are located at said target site, and detecting the accumulated, labelled CXC chemokine so as to image said target site.
A method of delivering a labeling agent to a target site of an animal's body, comprising introducing into an animal's body a CXC chemokine carrying a radionuclide labeling agent, wherein C stands for cysteine and X stands for an amino acid, and allowing the labeling agent-carrying CXC chemokine to accumulate at a target site, wherein neutrophils having Interleukin-8 receptor molecules are located at said target site, so as to deliver said labeling agent to said target site.
A method of delivering a radioactive agent to a target site of an animal's body comprising introducing into an animal's body a CXC chemokine carrying a radioactive agent, wherein C stands for cysteine and X stands for an amino acid, and allowing the radioactive agent-carrying CXC chemokine to accumulate at a target site, wherein neutrophils having Interleukin-8 receptor molecules are located at said target site, so as to deliver said radioactive agent to said target site.
A composition comprising a CXC chemokine carrying a radioactive labeling agent, wherein said radioactive labeling agent is selected from the group consisting of indium-111, and technetium-99m.
Dependencies are inferred from the claim text.